126 results about "Cardiac troponins" patented technology

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

The invention relates to a hybridoma cell capable of secreting anti-cardiac troponin I monoclonal antibodies, which can be rapidly and conveniently applied to hcTnI detection; and the invention also relates to a monoclonal antibody secreted by the hybridoma cell and the application thereof in the field of detecting cardiac troponin I. The hybridoma cell is preserved in the Preservation Center of Wuhan University at Mountain Lojia, Wuchang, Wuhan, Hubei (namely, China Center for Type Culture Collection), and the preservation number is CCTCC No: C201317. The secretion yield of the hybridoma cell is high, anti-cardiac troponin I monoclonal antibodies secreted by the hybridoma cell have the advantages of high affinity and high specificity and the like, and can be widely used in the detection field of anti-cardiac troponin I preparation, such as the fields of detection reagent or detection equipment preparation, and the like, and compared with traditional detection methods, the detection method has significant advantages in the aspects of specificity, sensitivity and detection rate and the like.

The present invention relates to a method for monitoring a subject suffering from heart failure, the method involving repeatedly determining, within given time intervals, the amounts of each of the following peptide markers: NT-proANP or a variant thereof; NT-proBNP or a variant thereof; a cardiac troponin or a variant thereof; and GDF-15 or a variant thereof; in a sample from the subject; and comparing the amounts measured in each determination with reference amounts of each marker; and assessing, based on differences in determined amounts in one or more of the markers, whether the subject is stable or has undergone a change in pathophysiological state.

The invention discloses a cardiac troponin kit based on a microfluidic chip, a preparation method thereof and a detection method of cardiac troponin. The preparation method comprises the steps of (1)coating the microfluidic chip; (2) performing fluorescent microsphere labeling; (3) assembling the microfluidic chip; (4) preparing a calibration article; (5) acquiring the cardiac troponin cTn1 kit based on the microfluidic chip. The cardiac troponin cTn1 kit performs measuring by means of a double-antibody sandwich method; high-sensitivity time-resolved phosphor is selected as a marker to perform antibody marking on fluorescent microspheres; analytical detection is performed via antibody pair immunoreaction; the performance of a reagent prepared herein may reach the level of same chemical light-emitting reagents. After immunoreaction, a washing liquid is used to fully remove surplus components; detecting and reading are performed on the fluorescent microspheres under immunoreaction bonding; the problem is avoided that the introduction of a developing liquid into the chip causes insufficiency of a chip or failure of timely post-rendering reading.

The invention relates to a high-sensitivity quantitative determination method of cardiac troponin I, and belongs to the technical field of biomedical detection. According to the detection method, specific recognition is conducted on the cardiac troponin I through an aptamer, and accurate and sensitive quantitative detection on cTnI is achieved by means of a rolling circle amplification technology of nucleic acid and a graphene oxide-based fluorescence resonance energy transfer technology; the detection method has the advantages of being good in specificity, high in sensitivity, easy and convenient to operate, low in cost and the like, and the clinical test requirements are met.

A method for screening a substance that inhibits the onset of anti-cardiac troponin I autoantibody-related disease, a pharmaceutical composition and a base material for therapy of cardiac disease that contains the substance obtained by aforesaid method thereof, a therapeutic apparatus that removes anti-troponin I autoantibody for aforesaid antibody related disease, a method of making an animal model for evaluating cardiac disease characterized by administrating anti-cardiac troponin I antibody, a method of selection of a therapeutic substance for cardiac disease characterized by using aforesaid animals, and a diagnosis of dilated cardiomyopathy characterized by measuring anti-cardiac troponin I autoantibody. An apparatus of the present invention that removes anti-cardiac troponin I antibody and a pharmaceutical composition for therapy of the antibody related disease may be useful for a therapy and / or prevention of cardiac disease.

The present invention provides methods and devices for detecting the presence of two or more threshold levels of an analyte, including markers of myocardial damage such as cardiac troponins, in a sample. In various embodiments, the invention provides convenient point-of-care tests for determining the condition of a patient, so as to guide cost effective health care.

The invention relates to a cardiac muscle control material, a preparation method therefor, a detection kit and a detection device for cardiac muscle. The cardiac muscle control material comprises quality control component and protection component, the quality control component comprises at least one of B-type natriuretic peptide, D-dimer, NT-proBNP, cardiac troponin I, myoglobin, creatine kinase isozyme and cardioid fatty acid binding protein and heart fatty acid binding protein. The protective component comprises 5 mM to 100 mM of a buffer agent, 0.5 % to 5% by weight of an excipient, 0.05 mMto 5 mM of an antioxidant, 0.05 mM to 15 mM of a protease inhibitor, 0.5% to 10% by weight of a stabilizer and 0.01% to 2% by weight of a surfactant. The cardiac muscle control material disclosed bythe invention is good in stability.

The present invention provides circulating biomarkers for conditions associated with metabolic syndrome, including diabetes mellitus, hypertension and congestive heart failure. The biomarkers include plasma DNA, neuron-specific enolase, 11β-hydroxysteroid dehydrogenase, rhodopsin, retinoschisin, RPE65 and cardiac troponin T. Methods and kits for detecting these biomarkers in the prediction, monitoring and diagnosing of disease are provided, particularly for determining mRNA levels thereof in a subject's blood.

The invention discloses a cardiac troponin (cTnI), myoglobin (Myo) and creatine kinase-MB (CK-MB) three-in-one colloidal gold test strip, a kit thereof and making methods of the test strip and the kit. The test strip and the kit are made through adopting a chromatographic technique and a double antibody sandwich principle, and the human cTnI, Myo and CK-MB levels in a clinic specimen (whole blood / serum / blood plasma) can be detected through one-time operation, so the operation process is simplified.

The invention relates to a detection kit for cardiac troponin I and a preparation method thereof. The detection kit for cardiac troponin I disclosed by the invention comprises an detection antibody and tracer-marked capture antibodies, wherein the capture antibodies are respectively two monoclonal antibodies combining different loci of the cardiac troponin I, and the detection antibody is a polyclonal antibody of the cardiac troponin I. The detection kit for cardiac troponin I and the preparation method thereof provided by the invention obviously improve the detection sensitivity and linear range, ensure accuracy and degree of precision at the same time, and can be used for efficient detection of cardiac troponin I by screening proper capture antibodies, detection antibody and combinationthereof detected by immunochromatography of the cardiac troponin I, and optimizing diluent components of the kit synchronously.

The invention relates to a method for preparing a sandwich type photoelectric chemical sensor for cardiac troponin I and belongs to the technical field of nano functional materials, immunoassay and photoelectrochemistry sensation. According to the method, a carboxylation CdS quantum dot is adopted to sensitize a 001 crystal surface of a nano square piece TiO2, then visible light absorption can beimproved, a composite material TiO2 / CdS of which the photoelectric activity is remarkably improved is prepared, by using a layer-by-layer self-assembling method, a cardiac troponin I antibody, bovineserum albumin and cardiac troponin I antigen are assembled on the composite material TiO2 / CdS, Ag@Cu2O shell-core nanoparticles are adopted as a second antibody marker, and by virtue of the excellentphotoelectric activity of the TiO2 / CdS and specific combination of antigen and antibodies of the cardiac troponin I, super-sensitive detection on the cardiac troponin I can be achieved, and the methodhas great significances for analysis and detection on the cardiac troponin I.

The invention relates to a cardiac troponin I rapid detection method. The cardiac troponin I rapid detection method is characterized by comprising the following steps: step (1): mixing nanoscale light sensitive microspheres with dyes inside, luminous microspheres coated by active molecules, active molecules labeled by biotins and a sample to be tested to obtain a mixture; step (2): carrying out incubation culture on the mixture, enabling components having immunological characteristics to react to obtain a compound; and step (3): irradiating the compound with exciting light to enable the compound to emit light, and determining by using a photon counter to obtain the detection value. The invention also provides a cardiac troponin I rapid detection kit. According to the cardiac troponin I rapid detection method and the corresponding detection kit, the detection result is stable, the accuracy is high, the cost is low, the sensitivity is high, the precision is high, the detection range is wide and the method and the kit are suitable for clinical expansion.

The invention discloses a method, system and chip test paper for parallel detection on various cardiac markers. The chip test paper is used for detecting a part or all of the cardiac markers including cTNI (cardiac troponin I), cTNT (cardiac troponin T), MYO (myoglobin), CK-MB (isoenzymeof creatine kinase containing M and B subunits), BNP (B-type natriuretic peptide), CRP (C-reactive protein) and FABP (fatty acid-binding protein); the chip test paper comprises a first membrane and a second membrane; a ligand An of each marker is arranged on the first membrane, and a ligand Bn coupled with a signal marker is absorbed on the second membrane; and a detected material forming sandwich detection together with the ligands An and Bn is added from a sampling hole, then under the acting force of percolation or other factors, the detected material moves to be combined with the ligands An and Bn respectively to form a composite array of the first membrane-the ligand An-the detected material-the ligand Bn-the signal marker, which is fixed on the first membrane, the composite array and a capture fiber membrane are assembled simultaneously, and a detection hole is reserved. The method, the system and the chip test paper provided by the invention can be used for detecting the various cardiac markers simultaneously and quantitatively; moreover, the detection sensitivity can be improved, and the detection time is saved.

The invention relates to a cardiac troponin I detection reagent, a preparation method and a cardiac troponin I detection kit. The cardiac troponin I detection reagent comprises a coated antibody solution, a detection antibody solution and an indicator solution, wherein the coated antibody comprises an antibody and stationary phase conjugate 1 obtained by coupling an antibody 1 with a stationary phase, and an antibody and stationary phase conjugate 2 obtained by coupling an antibody 2 with a stationary phase; the detection antibody is obtained by coupling an antibody 3 with a marker; and the indicator solution contains an indicator for quantitatively detecting the concentration of the marker. The invention also comprises the preparation method of the detection reagent and a kit using the detection reagent. In the invention, the antibody 2 and the antibody 3 can be respectively combined with the cardiac troponin I, so that the sufficient separation of the cardiac troponin I is facilitated, and the detection sensitivity of the reagent to the cardiac troponin I is further improved.

The invention discloses a cardiac troponin I magnetic particle chemiluminescence assay kit and a usage method thereof. The kit includes a plurality of reagent strips composed of a plurality of side-by-side hole sites. The reagent strip includes a cTnI magnetic microparticle reagent and a cTnI labeled reagent and further includes a sample diluent, a calibration product, a magnetic bead cleaning solution and a pre-exciting solution. A magnetic rod sleeve is arranged in one hole site on the reagent strip. By combination of a chemiluminescence technology and immunomagnetic particles, the cardiac troponin I magnetic particle chemiluminescence assay kit has higher detection sensitivity and specificity and better performance parameters; the flexibility is high; different tests can be performed simultaneously, a single test can also be carried out, so that shorter test time can be obtained, and the product cost is greatly reduced.

The invention discloses a double-resistant sandwich ELISA (enzyme linked immunosorbent assay) detection kit of human cardiac troponin I. A monoclonal antibody 7D2 is used as a capturing antibody; a monoclonal antibody 7H4 is used as a detection antibody, wherein a hybrid tumor cell strain 7D2 secreting the monoclonal antibody 7D2 is preserved in CCTCC (China Center For Type Culture Collection) onAugust 23th, 2017, and the preservation number is CCTCC NO: C2017120. A hybrid tumor cell strain 7H4 secreting the monoclonal antibody 7H4 is preserved in CCTCC on August 23th, 2017, and the preservation number is CCTCC NO: C2017121. The detection kit has the advantages that the sensitivity is high; the cost is low; a fast and efficient analysis means is provided for the detection of the human cardiac troponin I.

The invention relates to a hypersensitive cardiac troponin I detection method and a kit. The kit comprises a first group of antibodies and a second group of antibodies for detecting cardiac troponin Iin a sample from a subject, wherein the antibodies are selected from antibodies specifically binding to the following amino acid fragments: antibody 1: 13th to 29th sites; antibody 2: 27th to 39th sites; antibody 3: the 41st to 49th sites; and an antibody 4: the 85th to 92nd sites. The method and the kit disclosed by the invention are high in sensitivity and simple to operate, and can be used fordynamically monitoring the cardiac troponin I.

The invention belongs to the field of electrochemical detection and relates to to a composition for detecting troponin I, application of the composition, a magnetic microsphere electrochemiluminescence immunoassay kit and a detection method. The method is an electrochemical luminescence method; ruthenium pyridine is adopted as a chemiluminescence marker; the method has the obvious advantages of better sensitivity and better stability; ruthenium is a metal ion, the molecular weight of the ruthenium is small, and the steric hindrance of an antibody is not influenced; the method further has the advantages of short production process, good repeatability, wide detection range, controllable electrochemical luminescence reaction and reduced signal acquisition difficulty.

The invention relates to a troponin I competition turbidimetry detecting kit. Three minitype peptide fragments of human cardiac troponin I (cTnI) needed by setting artificial synthesis are used, the peptide fragments and inert carrier protein are coupled, and the peptide fragments and polystyrene latex microballoons prepared by antibodies having an effect on the minitype peptide fragments form reagents. The kit prepared by the immune latex reagents can be used by a semiautomatic or full-automatic developing analyzer for detecting cardiac troponin content in serum.

The invention provides a preparation method of carboxyl-modified functionalized graphene quantum dots, wherein the preparation method comprises the steps: preparing graphene oxide through an improved Hummer method, treating the prepared graphene oxide with a nitrogen-containing reagent to obtain N-doped graphene quantum dots, and modifying with organic acid to obtain carboxyl-modified graphene quantum dots. The carboxyl-modified functionalized graphene quantum dots prepared by the three-step method is simple in process, good in stability and high in fluorescence intensity, and has a prospect of being applied to detection of cardiac troponin I.

Theinvention relates to a latex enhanced immunoturbidimetric detection kit of cardiac troponin T.More precisely, the latex enhanced immunoturbidimetric detection kit comprises a first reagent and a second reagent, wherein the first reagent comprises a buffer solution, a stabilizer, a copolymer of 2-methyl allyl oxyethyl phosphonyl choline, and a preservative; and the second reagent comprises the buffer solution, latex granules bound with anti-human troponin T antibody, the stabilizer, and the preservative. The latex enhanced immunoturbidimetric detection kit of the cardiac troponin Thas a quantitative detection limit of about 0.1 ng / ml, the correlation with commercial chemiluminescence reagent is good, and can be applied to the clinical test of cTnT.

The invention belongs to the field of disease marker detection, photoelectron chemistry and immune sensor technique, and particularly discloses a preparation method of novel water-soluble Cd-Ag-Te quantum dot / nano-gold composite materials. According to the method, L-shaped glassy carbon electrodes are decorated, anti-cTnI (cardiac troponin I antibodies) are loaded, so that photoelectric immune sensors are established based on the novel water-soluble Cd-Ag-Te quantum dot / nano-gold composite materials, an LED (light-emitting diode) serves as an excitation light source, and cTnI (cardiac troponin I) specificity is detected based on immune reaction. According to the preparation method, water-soluble Cd-Ag-Te quantum dots, nano-gold and 405nm LED excitation light sources are introduced into cTnI photoelectric immune sensor systems, and the prepared photoelectric immune sensor is simple, economical, practical, simple and convenient to operate, good in selectivity, high in sensitivity and low in detection limit.

The invention relates to a novel isolated binding protein containing a cTnI antigen binding domain, and researches of the preparation, the applications and the like of the binding protein. The bindingprotein is high in activity, has high affinity with human cTnI protein, and can be widely applied to the field of cTnI protein detection.

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

The invention discloses a hybrid tumor cell strain 7D2 of human cardiac troponin I as well as a monoclonal antibody and application thereof. The hybrid tumor cell strain 7D2 is preserved in CCTCC (China Center For Type Culture Collection) on August 23th, 2017, and the preservation number is CCTCC NO C2017120. The monoclonal antibody 7D2 secreted by the hybrid tumor cell strain 7D2 is a cTnI rat derived monoclonal antibody with high affinity and high specificity; the cTnI in three forms of free cTnI, dipolymer compounds cTnI-C and tripolymer compounds cTnI-T-C can be combined, so that the monoclonal antibody can be used for detecting the cTnI content in serum; the foundation is laid for the development of a kit for fast detecting myocardial infarction.

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

The invention belongs to the field of gene engineering, and relates to a method for constructing mutant libraries of single-chain antibodies T of cTnI (cardiac troponin I). The method has the advantages that bacteria pRSF-Autodisplay are used as carriers, the capacity of each library can reach 1.5*10<5>, and the libraries are excellent in diversity as proved by DNA (deoxyribonucleic acid) sequencing; cTnI antigens from the fully humanized single-chain antibody libraries of the cTnI are used as targets by the aid of bacterium display technologies, and the humanized single-chain antibodies of the cTnI can be conveniently acquired after multiple screening cycles; the single-chain antibodies are recombinant antibodies, antibody heavy-chain variable regions and light-chain variable regions are connected with one another by a linker peptide by the aid of a gene engineering process to form each recombinant antibody, the single-chain antibodies are the smallest functional antibody fragments for keeping the antigen affinity activity and the specificity of parent antibodies, can obtained by means of in-vitro expression by the aid of gene engineering technologies and can be economically manufactured in the bacteria on a large scale, accordingly, immune detection antibodies can be easily, conveniently and economically manufactured, the detection reagent expenses can be greatly reduced, and the humanized single-chain antibody libraries are high in sensitivity and specificity, easy and convenient to operate and suitable for screening large quantities of samples, and have extremely broad application prospects.

The invention relates to creation of cardiac troponin I immunosensors on the basis of flaky copper sulfur molybdate, and belongs to the technical field of creation of novel sensors. Graphene / the flakycopper sulfur molybdate / manganese-doped cadmium sulfide are used as substrate materials, and ultraviolet-visible light irradiates on the substrate materials to obtain light currents. The creation hasthe advantages that flaky copper sulfur molybdate and manganese-doped cadmium sulfide energy bands in the substrate materials are excellently matched with one another, the electron transport capacitycan be improved by the graphene, and accordingly the photoelectric conversion efficiency can be greatly improved; effects of quenching the light currents can be realized by cardiac troponin I, the to-be-detected cardiac troponin I is different in quantity, and accordingly the degrees of influence on photoelectric signals can be different from one another; the cardiac troponin I can be detected bythe created immunosensors, and the detection limit of the cardiac troponin I immunosensors is 0.18 pg / mL.